Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Escudier

Showing results (71-80 of 362) with videos related to

Pageof 37
Sort By:
Archives of Dermatology|July 23, 2008
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitorJulien Autier, Bernard Escudier, Janine Wechsler, et al.
Biochimica Et Biophysica Acta|October 19, 2013
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanismsMagdalena Buczek, Bernard Escudier, Ewa Bartnik, et al.
The Oncologist|November 4, 2016
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell CarcinomaRobert J Motzer, Bernard Escudier, Andrew Gannon, et al.
European Urology|June 24, 2026
Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell CarcinomaRonan Flippot, Luigi Roca, Mariangela Calabrese, et al.
Clinical Genitourinary Cancer|October 19, 2013
Reversible posterior leukoencephalopathy syndrome induced by axitinibAntonin Levy, Lyes Benmoussa, Samy Ammari, et al.
Journal of the American Academy of Dermatology|November 26, 2008
Dermatologic symptoms associated with the multikinase inhibitor sorafenibCaroline Robert, Christina Mateus, Alain Spatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2009
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinomaChrystelle Brignone, Bernard Escudier, Caroline Grygar, et al.
European Urology|December 31, 2010
Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteriaPierre I Karakiewicz, Maxine Sun, Joaquin Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation TrialCarol Peña, Chetan Lathia, Minghua Shan, et al.
Annals of Internal Medicine|August 17, 2005
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?Caroline Robert, Sandrine Faivre, Eric Raymond, et al.
Pageof 37

Showing results (71-80 of 362) with videos related to

Sort By:
Pageof 37
Archives of Dermatology|July 23, 2008
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitorJulien Autier, Bernard Escudier, Janine Wechsler, et al.
Biochimica Et Biophysica Acta|October 19, 2013
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanismsMagdalena Buczek, Bernard Escudier, Ewa Bartnik, et al.
The Oncologist|November 4, 2016
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell CarcinomaRobert J Motzer, Bernard Escudier, Andrew Gannon, et al.
European Urology|June 24, 2026
Re: Circulating Kidney Injury Molecule-1 (KIM-1) and Association with Outcome to Adjuvant Immunotherapy in Renal Cell CarcinomaRonan Flippot, Luigi Roca, Mariangela Calabrese, et al.
Clinical Genitourinary Cancer|October 19, 2013
Reversible posterior leukoencephalopathy syndrome induced by axitinibAntonin Levy, Lyes Benmoussa, Samy Ammari, et al.
Journal of the American Academy of Dermatology|November 26, 2008
Dermatologic symptoms associated with the multikinase inhibitor sorafenibCaroline Robert, Christina Mateus, Alain Spatz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2009
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinomaChrystelle Brignone, Bernard Escudier, Caroline Grygar, et al.
European Urology|December 31, 2010
Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteriaPierre I Karakiewicz, Maxine Sun, Joaquin Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation TrialCarol Peña, Chetan Lathia, Minghua Shan, et al.
Annals of Internal Medicine|August 17, 2005
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?Caroline Robert, Sandrine Faivre, Eric Raymond, et al.
Pageof 37